POIESIS: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Phase 3 Study of Navtemadlin As Add-on to Ruxolitinib in JAK Inhibitor-Naive Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

被引：0

作者：

Vachhani, Pankit ^{[1
]}

Rampal, Raajit ^{[2
]}

Bradley, Terrence ^{[3
]}

Harrison, Claire ^{[4
]}

Jain, Tania ^{[5
]}

Kuykendall, Andrew T. ^{[6
]}

Palandri, Francesca ^{[7
]}

Mascarenhas, John O. ^{[8
]}

Al-Ali, Haifa Kathrin ^{[9
]}

Passamonti, Francesco ^{[10
,11
]}

Nekhymchuk, Anna ^{[12
]}

Foss, Hilarie

Rothbaum, Wayne ^{[12
]}

Verstovsek, Srdan ^{[12
]}

Heidel, Florian ^{[13
]}

机构：

[1] Univ Alabama Birmingham, Div Hematol & Oncol, Birmingham, AL USA

[2] Mem Sloan Kettering Canc Ctr, New York, NY USA

[3] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA

[4] Guys & St Thomas NHS Fdn Trust, London, England

[5] Johns Hopkins Univ, Baltimore, MD USA

[6] Univ S Florida, Moffitt Canc Ctr, Tampa, FL USA

[7] IRCCS Azienda Osped Univ Bologna, Policlin S Orsola Malpighi, Ist Ematol Serygnoli, Bologna, Italy

[8] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY USA

[9] Univ Hosp Halle, Halle, Saale, Germany

[10] Fdn IRCCS CaGranda Osped Maggiore Policlin Milano, Dept Pathophysiol & Transplantat, Milan, Italy

[11] Univ Milan, Dipartimento Oncol & Oncoematol, Milan, Italy

[12] Kartos Therapeut Inc, Redwood City, CA USA

[13] Hannover Med Sch, Hannover, Germany

来源：

BLOOD | 2024年 / 144卷

关键词：

D O I：

10.1182/blood-2024-200966

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：18083 / 18084

页数：2

共 50 条

[21] Safety and Efficacy of Pelabresib in Combination With Ruxolitinib for JAK Inhibitor-Naive Patients With Myelofibrosis: Latest Data From the Phase 3 MANIFEST-2 Study
Mascarenhas, John
Rampal, Raajit K.
Grosicki, Sebastian
Chraniuk, Dominik
Abruzzese, Elisabetta
Bose, Prithviraj
Gerds, Aaron
Vannucchi, Alessandro M.
Palandri, Francesca
Lee, Sung-Eun
Gupta, Vikas
Lucchesi, Alessandro
Oh, Stephen T.
Kuykendall, Andrew T.
Patriarca, Andrea
Alvarez-Larran, Alberto
Mesa, Ruben
Kiladjian, Jean-Jacques
Talpaz, Moshe
Lavie, David
Harris, Morgan
Kays, Sarah-Katharina
Jegg, Anna Maria
Wu, Manlei
Brown, Barbara
Harrison, Claire
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S416 - S417
[22] Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor Treatment-Naive Patients with Myelofibrosis: Results of the MANIFEST-2 Randomized, Double-Blind, Phase 3 Study
Rampal, Raajit K.
Grosicki, Sebastian
Chraniuk, Dominik
Abruzzese, Elisabetta
Bose, Prithviraj
Gerds, Aaron T.
Vannucchi, Alessandro M.
Palandri, Francesca
Lee, Sung-Eun
Gupta, Vikas
Lucchesi, Alessandro
Oh, Stephen T.
Kuykendall, Andrew T.
Patriarca, Andrea
Alvarez-Larran, Alberto
Mesa, Ruben
Kiladjian, Jean-Jacques
Talpaz, Moshe
Harris, Morgan
Kays, Sarah-Katharina
Jegg, Anna-Maria
Li, Qing
Brown, Barbara
Harrison, Claire N.
Mascarenhas, John
BLOOD, 2023, 142
[23] PHASE 3 RANDOMIZED TRIAL OF MOMELOTINIB VERSUS RUXOLITINIB IN JAK INHIBITOR NAIVE PATIENTS WITH MYELOFIBROSIS: RESULTS OF THE SIMPLIFY-1 STUDY
Gotlib, J. R.
Kiladjian, J-J.
Catalano, J. V.
Devos, T.
Egyed, M.
Hellman, A.
McLornan, D. P.
Shimoda, K.
Winton, E. F.
Deng, W.
Dubowy, R. L.
Maltzman, J. D.
Cervantes, F.
Mesa, R. A.
HAEMATOLOGICA, 2017, 102 : 320 - 320
[24] Curcumin as Add-On to Antipsychotic Treatment in Patients With Chronic Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Study
Miodownik, Chanoch
Lerner, Vladimir
Kudkaeva, Natalie
Lerner, Paul P.
Pashinian, Artashez
Bersudsky, Yuly
Eliyahu, Ronen
Kreinin, Anatoly
Bergman, Joseph
CLINICAL NEUROPHARMACOLOGY, 2019, 42 (04) : 117 - 122
[25] Dorzagliatin add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial
Wenying Yang
Dalong Zhu
Shenglian Gan
Xiaolin Dong
Junping Su
Wenhui Li
Hongwei Jiang
Wenjuan Zhao
Minxiu Yao
Weihong Song
Yibing Lu
Xiuzhen Zhang
Huifang Li
Guixia Wang
Wei Qiu
Guoyue Yuan
Jianhua Ma
Wei Li
Ziling Li
Xiaoyue Wang
Jiao’e Zeng
Zhou Yang
Jingdong Liu
Yongqian Liang
Song Lu
Huili Zhang
Hui Liu
Ping Liu
Kuanlu Fan
Xiaozhen Jiang
Yufeng Li
Qing Su
Tao Ning
Huiwen Tan
Zhenmei An
Zhaoshun Jiang
Lijun Liu
Zunhai Zhou
Qiu Zhang
Xuefeng Li
Zhongyan Shan
Yaoming Xue
Hong Mao
Lixin Shi
Shandong Ye
Xiaomei Zhang
Jiao Sun
Ping Li
Tao Yang
Feng Li
Nature Medicine, 2022, 28 : 974 - 981
[26] Dorzagliatin add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial
Yang, Wenying
Zhu, Dalong
Gan, Shenglian
Dong, Xiaolin
Su, Junping
Li, Wenhui
Jiang, Hongwei
Zhao, Wenjuan
Yao, Minxiu
Song, Weihong
Lu, Yibing
Zhang, Xiuzhen
Li, Huifang
Wang, Guixia
Qiu, Wei
Yuan, Guoyue
Ma, Jianhua
Li, Wei
Li, Ziling
Wang, Xiaoyue
Zeng, Jiao'e
Yang, Zhou
Liu, Jingdong
Liang, Yongqian
Lu, Song
Zhang, Huili
Liu, Hui
Liu, Ping
Fan, Kuanlu
Jiang, Xiaozhen
Li, Yufeng
Su, Qing
Ning, Tao
Tan, Huiwen
An, Zhenmei
Jiang, Zhaoshun
Liu, Lijun
Zhou, Zunhai
Zhang, Qiu
Li, Xuefeng
Shan, Zhongyan
Xue, Yaoming
Mao, Hong
Shi, Lixin
Ye, Shandong
Zhang, Xiaomei
Sun, Jiao
Li, Ping
Yang, Tao
Li, Feng
NATURE MEDICINE, 2022, 28 (05) : 974 - +
[27] Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial
Verstovsek, Srdan
Mesa, Ruben A.
Gotlib, Jason
Gupta, Vikas
DiPersio, John F.
Catalano, John V.
Deininger, Michael W. N.
Miller, Carole B.
Silver, Richard T.
Talpaz, Moshe
Winton, Elliott F.
Harvey, Jimmie H., Jr.
Arcasoy, Murat O.
Hexner, Elizabeth O.
Lyons, Roger M.
Paquette, Ronald
Raza, Azra
Jones, Mark
Kornacki, Deanna
Sun, Kang
Kantarjian, Hagop
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2017, 10 : 1 - 14
[28] Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial
Srdan Verstovsek
Ruben A. Mesa
Jason Gotlib
Vikas Gupta
John F. DiPersio
John V. Catalano
Michael W. N. Deininger
Carole B. Miller
Richard T. Silver
Moshe Talpaz
Elliott F. Winton
Jimmie H. Harvey
Murat O. Arcasoy
Elizabeth O. Hexner
Roger M. Lyons
Ronald Paquette
Azra Raza
Mark Jones
Deanna Kornacki
Kang Sun
Hagop Kantarjian
Journal of Hematology & Oncology, 10
[29] Efficacy of add-on Danhong injection in patients with unstable angina pectoris: A double-blind, randomized, placebo-controlled, multicenter clinical trial
Chen, Lin
Fu, Guang
Hua, Qi
Zhu, Hai-Yan
Deng, Yue
Wu, Wei
Zhao, Yu-Jie
Yang, Xi-Yan
Yang, Bai-Song
Zhou, Ya-Bin
Liu, Jun
Yu, Ya-Nan
Chen, Bing-Wei
Wang, Xian
Wang, Zhong
JOURNAL OF ETHNOPHARMACOLOGY, 2022, 284
[30] Pelabresib Plus Ruxolitinib Combination Therapy in JAK Inhibitor-Naive Patients With Myelofibrosis in the Phase 3 MANIFEST-2 Study: Preliminary Evidence of Bone Marrow Recovery
Mascarenhas, John
Rampal, Raajit K.
Vannucchi, Alessandro M.
Gupta, Vikas
Oh, Stephen T.
Kuykendall, Andrew T.
Mesa, Ruben
Kiladjian, Jean-Jacques
Talpaz, Moshe
Kremyanskaya, Marina
Scandura, Joseph
Kraeft, Tabea
Eliane, Jean-Pierre
Chang, Tzuu-Wang
Cui, Jike
Kuffer, Christian
Boxhammer, Rainer
Harrison, Claire
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S417 - S418

← 1 2 3 4 5 →